THE SPECIAL DIABETES PROGRAM: WHAT POLICYMAKERS NEED TO KNOW

The Special Diabetes Program (SDP) is a federal program comprised of two components—the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians (SDPI). Congress created these programs in 1997 to advance research for type 1 diabetes at the National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK) and to provide treatment and education programs for type 2 diabetes among American Indians and Alaska Natives (AI/AN).

The Special Diabetes Program for Type 1 Diabetes has used this funding to advance research to:

- Delay the onset of type 1 diabetes
- Better understand the underlying causes of the disease
- Prevent, treat, and reverse complications associated with the disease

SDP SAVES LIVES

Research funded by SDP led to the discovery of a drug that delays the onset of type 1 diabetes, accelerated progress on an artificial pancreas, and discovered nearly 50 genes that influence the risk of developing type 1 diabetes. Additional research is needed to identify ways to prevent and cure type 1 diabetes.

Through SDPI, more than 300 treatment and education programs on type 2 diabetes have been implemented in AI/AN communities. The SDPI has helped decrease diabetes prevalence among AI/AN adults from 15.4% in 2013 to 14.6% in 2017, decreased hospitalizations 84% between 2000 and 2015 in AI/AN adults, and decreased diabetes-related deaths 37% from 1999 to 2017.

TAKE ACTION BEFORE SEPTEMBER 30

Despite the SDP’s success and bipartisan support, the program is in jeopardy. Funding for SDP will expire on September 30, 2023, unless Congress passes legislation to reauthorize the program. The Endocrine Society urges Congress to pass a long-term extension with the highest funding possible.

Short-term extensions of SDP are harmful to the program because SDP funding is needed to support research that will take multiple years to carry out. The lives of more than 114 million Americans living with or at-risk for developing diabetes are being changed through these critical programs. It is important that we continue to invest in the research needed to cure diabetes and support programs that will help prevent and treat the disease.

The Congressional Diabetes Caucus is currently circulating a letter supporting SDP funding. To sign onto this letter, please contact contact Vic_Goetz@shaheen.senate.gov or Maria_Olson@collins.senate.gov on the Senate side and Nimit.Jindal@mail.house.gov or Colleen.Malloy.White@mail.house.gov on the House side.